Matthew De Silva

Matthew De Silva is the Chief Operating Officer at Pathos, a position he has held since August 2021.1 He is an entrepreneur and investor with a background in healthcare and technology. In 2013, De Silva's father was diagnosed with Glioblastoma Multiforme, an aggressive form of brain cancer, which inspired him to pivot from his career in finance to biotech.1

De Silva founded Notable Labs in 2014, a company that uses advanced technology to screen thousands of FDA-approved drug combinations against a patient's cancer cells to identify personalized treatment options.1 He served as the Founder and CEO of Notable Labs from May 2014 to February 2020, and then as Founder & Executive Chairman until October 2023.1

In addition to his role at Pathos, De Silva is also:

• A Venture Partner at Builders VC (since January 2021)
• An Angel Investor & Syndicate Lead at Longtail Health Ventures (since March 2021)
• An Advisor and Angel Investor at ENDPOINT HEALTH (since September 2020)1

De Silva has received several recognitions for his work, including:

• 2017 Aspen Ideas Festival Spotlight Health Scholar
• 2017 PM360 ELITE 100
• Silicon Valley Business Journal 40 under 40 in 20191

Prior to his entrepreneurial ventures, De Silva worked in finance, including roles as a Portfolio Manager at Clarium Capital Management and an Analyst at Bank of America Merrill Lynch.1